CA2361081C - Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis - Google Patents

Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis Download PDF

Info

Publication number
CA2361081C
CA2361081C CA2361081A CA2361081A CA2361081C CA 2361081 C CA2361081 C CA 2361081C CA 2361081 A CA2361081 A CA 2361081A CA 2361081 A CA2361081 A CA 2361081A CA 2361081 C CA2361081 C CA 2361081C
Authority
CA
Canada
Prior art keywords
ifn
cpn10
beta
day
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2361081A
Other languages
English (en)
French (fr)
Other versions
CA2361081A1 (en
Inventor
Halle Morton
Alice Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
Original Assignee
University of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland filed Critical University of Queensland
Publication of CA2361081A1 publication Critical patent/CA2361081A1/en
Application granted granted Critical
Publication of CA2361081C publication Critical patent/CA2361081C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2361081A 1999-01-20 2000-01-20 Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis Expired - Fee Related CA2361081C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP8239 1999-01-20
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS

Publications (2)

Publication Number Publication Date
CA2361081A1 CA2361081A1 (en) 2000-07-27
CA2361081C true CA2361081C (en) 2010-09-21

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2361081A Expired - Fee Related CA2361081C (en) 1999-01-20 2000-01-20 Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis

Country Status (12)

Country Link
US (1) US20090214473A1 (cg-RX-API-DMAC10.html)
EP (1) EP1150703B1 (cg-RX-API-DMAC10.html)
JP (1) JP4691257B2 (cg-RX-API-DMAC10.html)
KR (1) KR100694011B1 (cg-RX-API-DMAC10.html)
AT (1) ATE313332T1 (cg-RX-API-DMAC10.html)
AU (2) AUPP823999A0 (cg-RX-API-DMAC10.html)
CA (1) CA2361081C (cg-RX-API-DMAC10.html)
DE (1) DE60024967T2 (cg-RX-API-DMAC10.html)
DK (1) DK1150703T3 (cg-RX-API-DMAC10.html)
ES (1) ES2255484T3 (cg-RX-API-DMAC10.html)
PT (1) PT1150703E (cg-RX-API-DMAC10.html)
WO (1) WO2000043033A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
BG66458B1 (bg) * 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) * 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
KR20020002376A (ko) 2002-01-09
EP1150703A1 (en) 2001-11-07
DE60024967T2 (de) 2006-08-17
CA2361081A1 (en) 2000-07-27
KR100694011B1 (ko) 2007-03-12
AU2527100A (en) 2000-08-07
EP1150703A4 (en) 2004-11-10
ES2255484T3 (es) 2006-07-01
JP4691257B2 (ja) 2011-06-01
WO2000043033A1 (en) 2000-07-27
PT1150703E (pt) 2006-05-31
JP2002535286A (ja) 2002-10-22
US20090214473A1 (en) 2009-08-27
DE60024967D1 (en) 2006-01-26
DK1150703T3 (da) 2006-05-29
AU771867B2 (en) 2004-04-01
ATE313332T1 (de) 2006-01-15
EP1150703B1 (en) 2005-12-21
AUPP823999A0 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
US20090214473A1 (en) Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis
US8454967B2 (en) Compositions and methods for modulating the immune system
US10953071B2 (en) Compositions and methods for treatment of intracellular damage and bacterial infection
US5624938A (en) Use of chloroquine to treat multiple sclerosis
US20140072530A1 (en) Treatment of hiv
Takagi et al. Growth hormone improves immune function and survival in burned mice infected with herpes simplex virus type 1
CN112135623B (zh) 与疾病的治疗有关的组合物和方法
US20110294736A1 (en) Compounds and methods for the treatment of autoimmune and inflammatory disease
KR100424212B1 (ko) 1형인터페론을포함하는자가-면역질환치료용조성물
Tsai et al. Interferon-γ inhibition suppresses experimental allergic neuritis: modulation of major histocompatibility complex expression on Schwann cells in vitro
US5122372A (en) Process for treatment of allergies
US5264208A (en) Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
US4512974A (en) Treatment of protein malnourished surgical patients
Fleishman et al. Morphometry of Mast Cells in the Tongue Tissues of the White Rats under Stress Conditions
US20060063713A1 (en) Methods for restoring immune balance for the treatment of T-cell mediated diseases
CA2471586A1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140121